Immunic (IMUX) Total Current Liabilities (2013 - 2026)

Immunic (IMUX) has 14 years of Total Current Liabilities data on file, last reported at $38.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 49.9% year-over-year to $38.4 million; the trailing twelve-month figure through Mar 2026 stood at $38.4 million (up 49.9% YoY), and the FY2025 full-year result was $30.6 million, up 38.07% from the prior year.
• Total Current Liabilities climbed to $38.4 million in Q1 2026, from $30.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $38.4 million in Q1 2026 to a low of $10.4 million in Q2 2022.
• A 5-year average of $21.4 million and a median of $22.2 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities fell 29.95% in 2022 and soared 89.1% in 2023, its largest moves.
• Tracing IMUX's Total Current Liabilities over 5 years: stood at $13.1 million in 2022, then soared by 89.1% to $24.7 million in 2023, then slipped by 10.33% to $22.2 million in 2024, then jumped by 38.07% to $30.6 million in 2025, then rose by 25.3% to $38.4 million in 2026.
• Business Quant data shows IMUX's Total Current Liabilities at $38.4 million in Q1 2026, $30.6 million in Q4 2025, and $30.1 million in Q3 2025.